Autologous gene-modified cellular therapy composed of a dual population of CD5-knockout T cells and CD5-knockout anti-CD5 CAR-T cells, engineered to target CD5+ malignant T cells and prevent fratricide; administered as a single IV infusion.
Autologous gene-edited therapy comprising CD5-knockout anti-CD5 CAR-T cells (plus CD5-knockout T cells) that recognize CD5 on malignant T cells. CAR engagement activates T-cell cytotoxicity to kill CD5+ tumor cells, while CD5 knockout prevents fratricide and may relieve inhibitory CD5 signaling to enhance persistence and function.
YES
DIRECT
Anti-CD5 CAR T cells recognize CD5 on target cells, activate, and kill them via perforin/granzyme-mediated cytolysis and Fas-FasL apoptosis.
Intravenous anti-CD20 monoclonal antibody that depletes CD20+ B cells via complement-mediated cytotoxicity, ADCC, and apoptosis.
Chimeric anti‑CD20 monoclonal antibody that binds CD20 on B cells and depletes them via complement-dependent cytotoxicity, antibody‑dependent cellular cytotoxicity, and induction of apoptosis.
YES
DIRECT
Rituximab binds CD20 on B cells and triggers complement-dependent cytotoxicity and Fc-mediated ADCC/ADCP, leading to lysis and apoptosis of CD20+ cells.
Oral BCL-2 inhibitor (BH3 mimetic) that restores mitochondrial apoptosis by inhibiting anti-apoptotic BCL-2.
Selective oral BH3-mimetic that inhibits anti-apoptotic BCL-2, restoring mitochondrial apoptosis by promoting MOMP and caspase activation in BCL-2–dependent tumor cells; spares BCL-XL to reduce thrombocytopenia.
YES
DIRECT
Venetoclax inhibits anti-apoptotic BCL-2, triggering mitochondrial outer membrane permeabilization, cytochrome c release, and caspase activation to induce intrinsic apoptosis in BCL-2-dependent cells.
Anti-CD47 monoclonal antibody that blocks the CD47–SIRPα 'don't-eat-me' signal to enhance macrophage-mediated phagocytosis.
Humanized anti-CD47 monoclonal antibody that blocks the CD47–SIRPalpha 'don't-eat-me' checkpoint, enabling macrophage-mediated phagocytosis of tumor cells and promoting downstream anti-tumor T-cell responses.
YES
DIRECT
Anti-CD47 antibody blocks the CD47–SIRPα ‘don’t‑eat‑me’ signal and opsonizes CD47+ cells; macrophages engage the Fc region via Fcγ receptors and perform antibody-dependent cellular phagocytosis, killing the target cells (with secondary T-cell responses).
Anti-CD20 chimeric monoclonal antibody that depletes B cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis.
Chimeric anti-CD20 monoclonal antibody that depletes CD20-positive B cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and induction of apoptosis.
YES
DIRECT
Binds CD20 on B cells, triggering complement-dependent cytotoxicity and Fc-mediated ADCC (e.g., NK cells/macrophages), and can also induce apoptosis.